

OTC Pink Basic Disclosure Guidelines – 3Q17

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

Scrypt, Inc. – Name Changed to Scrypt, Inc. from SecureCare Technologies, Inc. on January 27, 2014.

2) Address of the issuer's principal executive offices

Company Headquarters

Address 1: 9050 N. Capital of Texas Hwy

Address 2: Suite III-250

Address 3: Austin, Texas 78759

Phone: 888-447-3707

Email: lfenelon@scryptinc.com

Website(s): www.scryptinc.com

IR Contact

Address 1: 9050 N. Capital of Texas Hwy

Address 2: Suite III-250

Address 3: Austin, Texas 78759

Phone: 888-447-3707

Email: lfenelon@scryptinc.com

Website(s): www.scryptinc.com

3) Security Information

Trading Symbol: SYPT

Exact title and class of securities outstanding: Common Stock

CUSIP: 81111J104

Par or Stated Value: \$.001

Total shares authorized: 55,000,000

as of: 09/30/2017

Total shares outstanding: 48,125,421

as of: 09/30/2017

Additional class of securities (if necessary):

Trading Symbol: _____

Exact title and class of securities outstanding: _____

CUSIP: _____

Par or Stated Value: _____

Total shares authorized: _____

as of: _____

Total shares outstanding: _____

as of: _____

Transfer Agent

Name: Pacific Stock Transfer Company

Address 1: 6725 Via Austi Pkwy

Address 2: Suite 300

Address 3: Las Vegas, Nevada 89119

Phone: 702-361-3033

Is the Transfer Agent registered under the Exchange Act?*

Yes: ☒

No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

A majority of the outstanding shares of common stock of Scrypt, Inc. bear a restrictive legend as follows: "The shares of stock represented by this certificate have not been registered under the Securities Act of 1933, as amended, and may not be sold or otherwise transferred unless a compliance with the registration provisions of such Act has been made or unless availability of an exemption from such registration provisions has been established, or unless sold pursuant to Rule 144 under the Securities Act of 1933".

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

Effective December 31, 2014, Scrypt, Inc. merged with California-based Axacore, Inc.

Effective February 29, 2016, Scrypt, Inc. merged with Texas-based J&H Medsoft, Limited Liability Company, doing business as DocbookMD ("DocbookMD").

Effective October 2, 2017, the Board of Directors of Scrypt, Inc. declared a Common Stock dividend of \$0.2077 per share to Shareholders of Record as of October 12, 2017, payable October 19, 2017.

Effective October 2, 2017 the Board of Directors of Scrypt, Inc. declared a Series A Preferred Stock Dividend of \$0.05 per share to Shareholders of Record as of October 12, 2017, payable October 19, 2017.

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

Reversion of 348,885 Shares of Common Stock back to Scrypt, Inc. on February 28, 2017

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

Pursuant to the Agreement and Plan of Merger between Scrypt, Inc. and J&H Medsoft, LLC (DBA DocbookMD) dated February 29, 2016, certain shares of Scrypt's Common Stock were placed in escrow and made subject to reversion to Scrypt if Actual Target Billings (as defined in the Merger Agreement) for the First Earnout Period (as defined in the Merger Agreement) fell short of the Earn Out Target (as defined in the Merger Agreement). As of February 28, 2017, the conditions for reversion of a portion of the Escrow Shares were met; therefore a total of 348,885 shares of Common Stock were reverted back to Scrypt on February 28, 2017.

B. Any jurisdictions where the offering was registered or qualified;

N/A

C. The number of shares offered;

N/A

D. The number of shares sold;

N/A

E. The price at which the shares were offered, and the amount actually paid to the issuer;

N/A

F. The trading status of the shares; and

All of the common stock shares reported above have not been registered and are restricted shares.

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes, all of the common stock certificates bear a restrictive legend as indicated above.

Issuance of Common Stock Shares Associated with the Merger of Scrypt, Inc. with J&H Medsoft, LLC (DBA DocbookMD) on February 29, 2016.

H. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

February 29, 2016 – A total of 2,424,692 shares of common stock were issued by Scrypt, Inc. to the membership holders of DocbookMD as purchase consideration for its merger with DocbookMD effective February 29, 2016.

I. Any jurisdictions where the offering was registered or qualified;

N/A

J. The number of shares offered;

N/A

K. The number of shares sold;

N/A

L. The price at which the shares were offered, and the amount actually paid to the issuer;

N/A

M. The trading status of the shares; and

All of the common stock shares reported above have not been registered and are restricted shares.

N. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes, all of the common stock certificates bear a restrictive legend as indicated above.

2014 Private Placement of Common Stock – January 1, 2014 through September 30, 2014

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

2014 – Private Placement Sale of Common Stock

B. Any jurisdictions where the offering was registered or qualified;

2014 - Europe

C. The number of shares offered;

2014 – 2,500,000

D. The number of shares sold;

880,000

E. The price at which the shares were offered, and the amount actually paid to the issuer;

\$0.30 per share offering price; \$264,000 actually paid to Scrypt, Inc.

F. The trading status of the shares; and

All of the common stock shares reported above have not been registered and are restricted shares.

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes, all of the common stock certificates bear a restrictive legend as indicated above.

Issuance of Restricted Stock Award Shares of Common Stock (RSA shares)

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

September 22, 2014 – A total of 5,515,748 Restricted Stock Award shares of common stock (RSA shares) were granted by the Board of Directors to certain employees of Scrypt, Inc. A total of 1,502,359 RSA shares vested immediately and the balance of 4,013,389 RSA shares vested on November 19, 2014.

B. Any jurisdictions where the offering was registered or qualified;

N/A

C. The number of shares offered;

N/A

D. The number of shares sold;

N/A

E. The price at which the shares were offered, and the amount actually paid to the issuer;

N/A

F. The trading status of the shares; and

All of the common stock shares reported above have not been registered and are restricted shares.

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes, all of the common stock certificates bear a restrictive legend as indicated above.

Issuance of Common Stock Shares Associated with the Merger of Scrypt, Inc. with Axacore, Inc. on December 31, 2014

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

December 31, 2014 – A total of 10,900,000 shares of common stock were issued by Scrypt, Inc. to the principal owners of Axacore, Inc. as purchase consideration for its merger with Axacore, Inc. effective December 31, 2014.

B. Any jurisdictions where the offering was registered or qualified;

N/A

C. The number of shares offered;

N/A

D. The number of shares sold;

N/A

E. The price at which the shares were offered, and the amount actually paid to the issuer;

N/A

F. The trading status of the shares; and

All of the common stock shares reported above have not been registered and are restricted shares.

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes, all of the common stock certificates bear a restrictive legend as indicated above.

2014 Common Stock Shares Issued in Conjunction with the Termination of the Technology License Agreement with SecureCare Technologies, Inc. UK LTD. – Shares Issued on February 13, 2014

A. The nature of each offering (e.g., Securities Act Rule 504, intrastate, etc.);

February 13, 2014 – A total of 700,000 common stock shares were issued by the Board of Directors in conjunction with the termination of the Technology License Agreement with SecureCare Technologies, Inc. UK Ltd.

B. Any jurisdictions where the offering was registered or qualified;

N/A

C. The number of shares offered;

N/A

D. The number of shares sold;

N/A

E. The price at which the shares were offered, and the amount actually paid to the issuer;

N/A

F. The trading status of the shares; and

All of the common stock shares reported above have not been registered and are restricted shares.

G. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

Yes, all of the common stock certificates bear a restrictive legend as indicated above.

5) Financial Statements

Provide the financial statements described below for the most recent fiscal year end or quarter end to maintain qualification for the OTC Pink Current Information tier. For the initial disclosure statement (qualifying for Current Information for the first time) please provide reports for the two previous fiscal years and any interim periods.

- A. Balance sheet;
- B. Statement of income;
- C. Statement of cash flows;
- D. Financial notes; and
- E. Audit letter, if audited

The financial statements requested pursuant to this item shall be prepared in accordance with US GAAP by persons with sufficient financial skills.

You may either (i) attach/append the financial statements to this disclosure statement or (ii) post such financial statements through the OTC Disclosure & News Service as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial reports separately as described in part (ii) above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to otcq.com in the field below.

Script, Inc. Unaudited Financial Statements for the Nine Months Ended September 30, 2017; posted to otcq.com on January 31, 2018.

Information contained in a Financial Report is considered current until the due date for the subsequent Financial Report. To remain in the OTC Pink Current Information tier, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of its fiscal quarter-end date.

6) Describe the Issuer's Business, Products and Services

- A. a description of the issuer's business operations;

Script, Inc. builds powerful productivity tools that help customers in regulated industries, especially healthcare and lending, improve collaboration and workflow while protecting sensitive and business-critical information.

Effective February 27, 2014, the Company changed its name from SecureCare Technologies, Inc. to Script, Inc.

The company merged with Axacore, Inc. on December 31, 2014.

The company merged with J&H Medsoft Limited Liability Company, doing business as DocbookMD ("DocbookMD") on February 29, 2016.

The company sold Sfax™, one of its main product brands, on March 31, 2017 to j2 Global, Inc.

The company discontinued operations related to Stak™ on July 31, 2017.

The Company's three main product brands are DocbookMD™, XDOC™ and FaxAgent™.

DocbookMD™ is a HIPAA-secure healthcare messaging and care collaboration platform for the entire care team. Through an integrated directory of providers, the platform was designed to enable physicians to collaborate on vital information including detailed images, labs, X-rays and EKGs, and to communicate effectively with their entire care team.

XDOC™ is an Electronic Document Management (EDM) platform to help simplify the mortgage lending process. XDOC™ works in tandem with Loan Origination Systems (LOS) to capture, manage, locate, classify, and deliver loan documents throughout the loan lifecycle.

FaxAgent™ provides enterprise fax technology for telecommunication carriers or service providers that wish to incorporate reliable, high performance and scalable faxing technology into their offering.

The Company markets its services to customers throughout the United States; currently operating from its Austin, Texas-based corporate headquarters. Effective December 31, 2014 in its merger with Axacore, Inc. the company now operates out of one additional location, San Diego, California.

B. Date and State (or Jurisdiction) of Incorporation:

June 1998; State of Nevada

C. the issuer's primary and secondary SIC Codes;

SIC Code: 5734 and NAICS Code: 443120

D. the issuer's fiscal year end date;

December 31

E. principal products or services, and their markets;

The Company's three main product brands are DocbookMD™, XDOC™ and FaxAgent™.

DocbookMD™ is a HIPAA-secure healthcare messaging and care collaboration platform for the entire care team. Through an integrated directory of providers, the platform was designed to enable physicians to collaborate on vital information including detailed images, labs, X-rays and EKGs, and to communicate effectively with their entire care team.

XDOC™ is an Electronic Document Management (EDM) platform to help simplify the mortgage lending process. XDOC™ works in tandem with Loan Origination Systems (LOS) to capture, manage, locate, classify, and deliver loan documents throughout the loan lifecycle.

FaxAgent™ provides enterprise fax technology for telecommunication carriers or service providers that wish to incorporate reliable, high performance and scalable faxing technology into their offering.

The Company markets its services to customers throughout the United States; currently operating from its Austin, Texas-based corporate headquarters. Effective December 31, 2014 in its merger with Axacore, Inc. the company now operates out of one additional location, San Diego, California.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company's principal executive office is in Austin, Texas. The Company has a non-cancelable operating lease agreement there for 8,587 rentable square feet, which expires on August 31, 2018. Effective December 31, 2014 in its merger with Axacore, Inc. the company operates out of one additional location. An office is maintained in San Diego, California. This office has a non-cancelable operating lease agreement for 3,593 rentable square feet, which expires on February 15, 2017. Effective May 1, 2016 the San Diego office lease was re-negotiated and extended through April 30, 2022.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

- A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Aleksander Szymanski, Executive Chairman, Director and Control Person

Neil Burley, Corporate Secretary

Nick Basil, Chief Technology Officer, Director and Control Person

Michael Senter, Chief Revenue Officer

Monica Hatchett, Chief Product Officer

Eugene Fry, Chief Compliance Officer

Joseph Larter, Director and Control Person

Richard Corlin, Director and Chief Medical Officer

Richard Smith, Director

Timothy Gueramy, Director

David McCall, Control Person

Traci Basil, Control Person

Andrew Basil, Control Person

Kevin Slinde, Control Person

- B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Name: Diana Borden

Firm: Hajjar Peters LLP

Address 1: 3144 Bee Caves Road

Address 2: Austin, Texas 78746

Phone: 512-637-4956

Email: dborden@legalstrategy.com

Legal Counsel

Name: Frank J Hariton

Firm:

Address 1: 1065 Dobbs Ferry Road

Address 2: White Plains, New York 10607

Phone: 914-674-4373

Email: hariton@sprynet.com

Accountant or Auditor

Name: Chris Bauer, Managing Partner

Firm: Bauer & Company

Address 1: 5910 Courtyard Drive, Suite 230

Address 2: Austin, Texas 78731

Phone: 512-731-3518

Email: chris@teambauer.com

Investor Relations Consultant

Name: N/A

Firm: N/A
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

Name: N/A
Firm: N/A
Address 1: _____
Address 2: _____
Phone: _____
Email: _____

10) Issuer Certification – Executive Chairman

I, Aleksander Szymanski certify that:

1. I have reviewed this Quarterly Disclosure Statement of Scrypt, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

1/31/18

/S/ Aleksander Szymanski, Executive Chairman and Member of the Board of Directors

10) Issuer Certification – Financial Controller

I, Laura Fenelon certify that:

1. I have reviewed this Quarterly Disclosure Statement of Scrypt, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

1/31/18

/S/ Laura Fenelon, Financial Controller